Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CLB · NYSE · United States · Oil & Gas Field Services, Nec
In shortCore Laboratories Inc. /DE/ is profitable, generates cash and carries moderate debt, with revenue stable (+0.5% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 10.7% | 52/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 5.6% | 43/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 11.6% | 58/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 9.9% | 66/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.02× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.41× | 88/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.23× | 79/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.34× | 37/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.71 | 67/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 4.9% | 40/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.87× | 71/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 4 | 100/100 |
| Revenue growth volatility | 1.7% | 100/100 |
| Operating margin volatility | 1.1% | 99/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.4% | 30/100 |
|---|---|---|
| EPS growth, 3-year average | 14.5% | 97/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 470 | 490 | 510 | 524 | 527 |
| Cost of revenue | – | 394 | 400 | 421 | 418 |
| Gross profit | – | 96 | 110 | 103 | 109 |
| Operating income | 45 | 42 | 55 | 59 | 56 |
| Interest expense | 9.2 | 12 | 13 | 12 | 11 |
| Pre-tax income | 36 | 30 | 41 | 46 | 46 |
| Income tax | 16 | 10 | 4.2 | 14 | 16 |
| Net income | 20 | 19 | 37 | 31 | 30 |
| Diluted EPS | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 |
| Diluted shares (millions) | 47 | 47 | 48 | 48 | 47 |
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of Core Laboratories Inc. /DE/ are included in the Investor plan. Try free for 7 days →
3.71 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 30, 2026